Clonal haematopoiesis (CH) is a ubiquitous feature of aging and provides mechanistic
insight into the inextricable relationship between chronic inflammation and age-related
diseases. Although CH confers a cumulative risk of subsequent haematological malignancy,
particularly myeloid neoplasms, that risk is heavily mutation-and context-specific. Individuals
with mutations in DNA damage response pathway genes receiving select cytotoxic therapies
for solid tumours are among the highest risk groups for subsequent development of myeloid …